Jake Simson, PhD
Jake Simson is a Partner at RA Capital Management. Jake works on both public and private investments and serves as a Board Director for DICE Therapeutics, Janux Therapeutics, Tyra Biosciences, Bicara Therapeutics, and Convergent Therapeutics. Previously, Jake covered solid tumor oncology landscapes.
Jake holds a B.S. in Materials Science and Engineering from MIT and a PhD in Biomedical Engineering from Johns Hopkins University. In his doctoral research, he investigated clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels.